Search results
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 3 days agoWe covered in detail results from a few of the most significant, including for AstraZeneca and...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 4 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 3 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...
Health Care Roundup: Market Talk
The Wall Street Journal· 7 days agoKeytruda is the world’s top-selling drug and raked in about $25 billion in revenue for Merck last year. (ben.glickman@wsj.com; @benglickman) 1151 ET – ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoTruqap™ (capivasertib) plus fulvestrant now available in Canada Canada NewsWire MISSISSAUGA, ON, May 31, 2024 MISSISSAUGA, ON, May 31, 2024 /CNW/ - AstraZeneca is pleased ...
Move over 'Magnificent 7,' the 'Fantastic 5' may offer higher earnings and return potential
CNBC· 5 hours agoLooking for a less risky way to find growth stocks amid all the artificial intelligence hype?...
Cramer's Lighting Round: ‘You've got a winner' with Astra Zeneca
NBC Los Angeles· 6 days ago“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to...
Novavax Stock Rallies In Pre-Market As Company Plans To Deliver Covid-19 Vaccine By September -...
Benzinga· 3 hours agoNovavax Inc. NVAX shares surged after the company announced its plans to deliver a...
Cancer Drugs: Deals and Licensing for Antibody-Drug Conjugates
The National Law Review· 19 hours agoAntibody-drug conjugates (ADCs) are a promising class of cancer treatments with an accelerating...
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
InvestorPlace· 5 hours agoThis however holds true for high-quality blue-chip and growth stocks. On the other hand, in an...